Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. [electronic resource]
Producer: 20031120Description: 532-40 p. digitalISSN:- 0022-3476
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antiviral Agents -- therapeutic use
- Comorbidity
- Double-Blind Method
- Heart Defects, Congenital -- epidemiology
- Hospitalization -- statistics & numerical data
- Humans
- Palivizumab
- Respiration, Artificial
- Respiratory Syncytial Virus Infections -- epidemiology
- Risk Factors
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.